
Tumour Necrosis Factor Alpha and Oxidative Stress in the Breath Condensate of Those with
Non-Small Cell Lung Cancer
465
doi:10.1016/j.lungcan.2008.05.020
[13] D. H. Conrad, J. Goyette and P. S. Thomas, “Proteomics
as a Method for Early Detection of Cancer: A Review of
Proteomics, Exhaled Breath Condensate, and Lung Can-
cer Screening,” Journal of General Internal Medicine,
Vol. 23, No. 1S, 2007, pp. 78-84.
[14] K. L. Reckamp, B. K. Gardner, R. A. Figlin, et al., “Tu-
mor Response to Combination Celecoxib and Erlotinib
Therapy in Non-Small Cell Lung Cancer Is Associated
with a Low Baseline Matrix Metalloproteinase-9 and a
Decline in Serum-Soluble E-Cadherin,” Journal of Tho-
racic Oncology, Vol. 3, No. 2, 2008, pp. 117-124.
doi:10.1097/JTO.0b013e3181622bef
[15] D. Derin, H. O. Soydinc, N. Guney, et al., “ Serum Lev-
els of Apoptosis Biomarkers and TNF-Alpha in Nonsmall
Cell Lung Cancer,” Lung Cancer, Vol. 59, No. 2, 2008,
pp. 240-245. doi:10.1016/j.lungcan.2007.08.005
[16] E. Dalaveris, T. Kerenidi, A. Katsabeki-Katsafli, et al.,
“VEGF, TNF-Alpha and 8-Isoprostane Levels in Exhaled
Breath Condensate and Serum of Patients with Lung Can-
cer,” Lung Cancer, Vol. 64, No. 2, 2009, pp. 219-225.
doi:10.1016/j.lungcan.2008.08.015
[17] P. W. Szlosarek and F. R. Balkwill, “Tumour Necrosis
Factor α: A Potential Target for the Therapy of Solid Tu-
mors,” The Lancet Oncology, Vol. 4, No. 1, 2003, pp.
565-573. doi:10.1016/S1470-2045(03)01196-3
[18] P. Montuschi and P. J. Barnes, “Analysis of Exhaled
Breath Condensate for Monitoring Airway Inflamma-
tion,” Trends in Pharmacological Sciences, Vol. 23, No. 5,
2002, pp. 232-237.
doi:10.1016/S0165-6147(02)02020-5
[19] K. Garey, M. M. Neuhauser, R. A. Robbins, L. H. Dan-
ziger and I. Rubinstein, “Markers of Inflammation in Ex-
haled Breath Condensate of Young Healthy Smokers,”
Chest, Vol. 125, No. 1, 2004, pp. 22-26.
doi:10.1378/chest.125.1.22
[20] D. Nowak, S. Kalucka, P. Białasiewicz and M. Król, “Ex-
halation of H2O2 and Thiobarbituric Acid Reactive Sub-
stances (TBARs) by Healthy Subjects,” Free Radical Bi-
ology & Medicine, Vol. 30, No. 2, 2001, pp. 178-186.
doi:10.1016/S0891-5849(00)00457-3
[21] S. Doruk, H. Ozyurt, H. Inonu, U. Erkorkmaz, O. Saylan
and Z. Seyfikli, “Oxidative Status in the Lungs Associ-
ated with Tobacco Smoke Exposure,” Clinical Chemistry
and Laboratory Medicine, 2011, in Press.
doi:10.1515/CCLM.2011.698
[22] H. P. Chan, C. R. Lewis and P. S. Thomas, “Oxidative
Stress and Exhaled Breath Analysis: A Promising Tool
for Detection of Lung Cancer,” Cancers, Vol. 2, No. 1,
2010, pp. 32-42. doi:10.3390/cancers2010032
[23] T. P. Szatrowski and C. F. Nathan, “Production of Large
Amounts of Hydrogen Peroxide by Human Tumor Cells,”
Cancer Research, Vol. 51, No. 3, 1991, pp. 794-798.
[24] M. D. Evans, M. Dizdaroglu and M. S. Cooke, “Oxida-
tive DNA Damage and Disease: Induction, Repair and
Significance,” Mutation Research, Vol. 567, No. 1, 2004,
pp. 1-61. doi:10.1016/j.mrrev.2003.11.001
[25] O. Vafa, M. Wade, S. Kern, et al., “c-Myc Can Induce
DNA Damage, Increased Reactive Oxygen Species, and
Mitigate p53 Function: A Mechanism for Oncogene-In-
duced Genetic Instability,” Molecular Cell, Vol. 9 No. 5,
2002, pp. 1031-1044.
doi:10.1016/S1097-2765(02)00520-8
[26] L. Hlavata, H. Aguilaniu, A. Pichova, et al., “The Onco-
genic RAS2val19 Mutation Locks Respiration, Inde-
pendently of PKA, in a Mode Prone to Generate ROS,”
European Molecular Biology Organization Journal, Vol.
22, No. 13, 2003, pp. 3337-3345.
doi:10.1093/emboj/cdg314
[27] H. Pelicano, D. Carney and P. Huang, “ROS Stress in
Cancer Cells and Therapeutic Implications,” Drug Resis-
tance Updates, Vol. 7, No. 1, 2004, pp. 97-110.
doi:10.1016/j.drup.2004.01.004
[28] D. R. Spitz, E. L. Azzam, J. J. Li and D. Gius, “Metabolic
Oxidation/Reduction Reactions and Cellular Responses to
Ionizing Radiation: A Unifying Concepts in Stress Re-
sponse Biology,” Cancer and Metastasis Reviews, Vol. 23,
No. 1, 2004, pp. 311-322.
doi:10.1023/B:CANC.0000031769.14728.bc
[29] J. E. Bigalow, J. B. Mitchell and K. Held, “The Impor-
tance of Peroxide and superoxide in the Xray Response,”
Internal Journal of radiation Oncology, Biology, Physics,
Vol. 22, No. 1, 1992, pp. 665-669.
[30] G. R. Buettner, “Ascorbate Oxidation: UV Absorbance of
Ascorbate and ESR Spectroscopy of the Ascorbyl Radical
as Assay for Iron,” Informa Healthcare, Vol. 10, No. 1-2,
1990, pp. 5-9.
[31] L. Boldrini, A. Calcinai, E. Samaritani, et al., “Tumour
Necrosis Factor-Alpha and Transforming Growth Fac-
tor-Beta Are Significantly Associated with Better Prog-
nosis in Non-Small Cell Lung Carcinoma: Putative Rela-
tion with BCL-2-Mediated Neovascularization,” British
Journal of Cancer, Vol. 83, No. 1, 2000, pp. 480-486.
doi:10.1054/bjoc.2000.1345
[32] L. Gibellini, M. Pinti, M. Nasi, et al., “Interfering with
ROS Metabolism in Cancer Cells: The Potential Role of
Quercetin,” Cancer, Vol. 2, No. 1, 2010, pp. 1288-1311.
[33] Z. Cheng, C. R. Lewis, P. S. Thomas, et al., “Compara-
tive Proteomics Analysis of Exhaled Breath Condensate
in Lung Cancer Patients,” Journal of Cancer Therapy,
Vol. 2, No. 1, 2011, pp. 1-8. doi:10.4236/jct.2011.21001
[34] I. Horvath, J. Hunt and P. J. Barnes, “Exhaled Breath
Condensate: Methodological Recommendations and Un-
resolved Questions,” European Respiratory Journal, Vol.
26, No. 3, 2005, pp. 523-548.
doi:10.1183/09031936.05.00029705
[35] F. Imer, E. Aldemir, H. Kilic, et al., “The Protective Ef-
fect of Amino Acids on the Copper(II)-Catalyzed Auto-
xidation of Ascorbic Acid,” Journal of Food and Drug
Analysis, Vol. 16, No. 6, 2008, pp. 46-53.
[36] M. N. Khan and A. Sarwar, “The Influence of Transition
Metal Ions on the Kinetics of Ascorbic Acid Oxidation by
Methylene Blue in Strongly Acidic Media,” Turkish
Journal of Chemistry, Vol. 25, No. 1, 2001, pp. 433-440.
Copyright © 2012 SciRes. JCT